April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas – Dana-Farber News
Jan 28, 2024, 18:44

Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas – Dana-Farber News

Dana-Farber News recently shared a post on their X/Twitter page:

ASCO GU24: Interim phase 1 results show HPN328, a T-cell engager, is well tolerated and clinically active for patients across a wide range of neuroendocrine carcinomas. Dana-Farber Cancer Institute’s Misha Beltran explains more here.”

Link to video.

Source: Dana-Farber News/X